CAESAREA, Israel and CLEVELAND, June 4, 2012 /PRNewswire/ -- IceCure Medical Ltd. announced the first four breast cancer patients treated with the IceSense3™ Cryoablation Procedure in Japan. The IceSense3 System was used to treat small breast cancer tumors in a minimally invasive procedure using ultrasound guidance and local anesthesia. These patients were the first four enrolled in a clinical trial of 30 small, early stage breast cancer patients at Kameda Medical Center in Kamogawa City, Japan.
Cryoablation has been used for years to treat both malignant and benign tumors in the body. This new system from IceCure Medical has been developed specifically for breast tumors, and can be performed comfortably with ultrasound guidance. The system uses extremely cold temperatures to destroy (ablate) breast tumors. An attractive alternative to open surgery, the IceSense3 procedure takes place in a physician's office or breast center, and doesn't require sutures or general anesthesia. The system is currently being used worldwide for treatment of fibroadenomas, benign breast tumors, and holds promise as a potential treatment option for malignant breast tumors.
"This procedure is an exciting step towards moving treatment of small, early stage breast cancer tumors from open surgery to a minimally invasive cryoablation procedure," stated Eisuke Fukuma, MD, PhD, Chairman of Breast Center, Kameda Medical Center (Kamogawa City, Japan). "Cryoablation offers a much more comfortable and cosmetically appealing treatment option for small breast cancers. The state-of-the-art IceSense3 system from IceCure provides a more efficient, targeted treatment to completely destroy the tumor in a quick, office procedure."
Dr. Fukuma has established the safety and efficacy of an early generation cryoablation system in treating selected breast cancer patients and following them for several years. His experience to date includes 37 cases treated over five years. The results have been promising, with no local recurrence or distant metastases. Further, the cosmetic results have been excellent with high patient satisfaction. "The IceSense3™ Cryoablation System represents an opportunity to further validate this minimally invasive approach with highly efficient, innovative technology," stated Dr. Fukuma.
"We are extremely excited to partner with Dr. Fukuma and expand on the groundbreaking work he initiated by treating small, early stage breast cancers with cryoablation," stated Hezi Himelfarb, President and CEO of IceCure Medical. "We believe the IceSense3 cryoablation procedure is the best method for treating appropriate breast tumors and Dr. Fukuma's study is a critical advancement towards providing less invasive and better cosmetic options for patients."
The IceSense3 Cryoablation System was designed for efficient and effective treatment of breast tumors. The procedure is typically 5-15 minutes in a physician's office. Physicians use ultrasound (sonographic) guidance throughout the procedure, to guide the small probe into the targeted breast tumor. The procedure is comfortable, virtually painless, and does not require sutures or sedation.
About IceCure Medical Ltd.
IceCure Medical Ltd. is a medical device company (TASE: ICCM) focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's tumors. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit: www.icecure-medical.com.
SOURCE IceCure Medical Ltd.